PulmCCM

Share this post
Phase III trials for aclidinium, a "me-too" antimuscarinic, in COPD (ACCLAIM I & II)
www.pulmccm.org

Phase III trials for aclidinium, a "me-too" antimuscarinic, in COPD (ACCLAIM I & II)

May 20, 2011
Share this post
Phase III trials for aclidinium, a "me-too" antimuscarinic, in COPD (ACCLAIM I & II)
www.pulmccm.org

Jones et al randomized 1,647 people with moderate to severe COPD for the two trials, to receive either aclidinium inhaled (a potential tiotropium competitor) once daily or placebo for 1 year. Aclidinium improved FEV1 by ~65 mL. An absolute ~8% more people taking the drug achieved a 4-point SGRQ improvement over those taking placebo. Time to exacerbation was reduced slightly compared to placebo in one of the trials (the overall exacerbation rate was low). There were no serious adverse events. (n=1,647) Respiratory Research 2011;12:55. FREE FULL TEXT

Share this post
Phase III trials for aclidinium, a "me-too" antimuscarinic, in COPD (ACCLAIM I & II)
www.pulmccm.org
Comments
TopNew

No posts

Ready for more?

© 2023 PulmCCM
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing